Advances in therapy · 2013
Comparative cross-sectional analysis of the effects of topical antiglaucoma drugs on the ocular surface.
Сравнительное исследованиеСтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lee Sangmoon, Kim Mee Kum, Choi Hyuk Jin, Wee Won Ryang, Kim Dong Myung
Аннотация
INTRODUCTION: The aim of this study was to comparatively analyze the effects of topical intraocular pressure (IOP)-lowering drugs on the ocular surface and to elucidate whether the main causative factor of toxicity is associated with benzalkonium chloride (BAK) or an active compound.
METHODS: The medical records of 300 eyes in 187 glaucoma patients that had instilled IOP-lowering drugs were cross-sectionally reviewed. Corneal epithelial punctuate erosion and tear break-up time (BUT) were quantitatively assessed. Durations of glaucoma, sums of concentrations of BAK in current medication (BAK(%sum)), and the presence of beta-blockers were investigated as risk factors (Institutional Review Board of Seoul National University Hospital, Seoul - IRB number: H-1007-103-324).
RESULTS: Age-adjusted BAK(%sum) was found to be significantly and positively correlated with corneal epithelial punctate erosion (P = 0.001, r = 0.208) and negatively correlated with BUT (P = 0.042, r = 0.131). BAK(%sum) adjusted corneal epithelial erosion was found to be significantly greater in beta-blocker containing eyedrop-instilled eyes (P = 0.016). No difference in ocular toxicity was found between carbonic anhydrase inhibitor and prostaglandin analog or between latanoprost- and travoprost-treated eyes.
CONCLUSION: Long-term treatment with BAK-containing antiglaucoma medication appears to be the main contributor to corneal toxicity and to do so in a dose-dependent manner. Formulations containing beta-blockers also appear to contribute to corneal toxicity.
METHODS: The medical records of 300 eyes in 187 glaucoma patients that had instilled IOP-lowering drugs were cross-sectionally reviewed. Corneal epithelial punctuate erosion and tear break-up time (BUT) were quantitatively assessed. Durations of glaucoma, sums of concentrations of BAK in current medication (BAK(%sum)), and the presence of beta-blockers were investigated as risk factors (Institutional Review Board of Seoul National University Hospital, Seoul - IRB number: H-1007-103-324).
RESULTS: Age-adjusted BAK(%sum) was found to be significantly and positively correlated with corneal epithelial punctate erosion (P = 0.001, r = 0.208) and negatively correlated with BUT (P = 0.042, r = 0.131). BAK(%sum) adjusted corneal epithelial erosion was found to be significantly greater in beta-blocker containing eyedrop-instilled eyes (P = 0.016). No difference in ocular toxicity was found between carbonic anhydrase inhibitor and prostaglandin analog or between latanoprost- and travoprost-treated eyes.
CONCLUSION: Long-term treatment with BAK-containing antiglaucoma medication appears to be the main contributor to corneal toxicity and to do so in a dose-dependent manner. Formulations containing beta-blockers also appear to contribute to corneal toxicity.